Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Products under Development by Stage of Development | 9 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Products under Development by Therapy Area | 10 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Products under Development by Indication | 11 | 2 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Products under Development by Companies | 15 | 3 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Products under Development by Universities/Institutes | 18 | 2 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Therapeutics Assessment | 20 | 7 |
| Assessment by Monotherapy/Combination Products | 20 | 1 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Companies Involved in Therapeutics Development | 27 | 7 |
| Aptose Biosciences Inc. | 27 | 1 |
| Conatus Pharmaceuticals Inc. | 28 | 1 |
| LG Life Science LTD. | 29 | 1 |
| New World Laboratories, Inc. | 30 | 1 |
| Novelix Pharmaceuticals, Inc. | 31 | 1 |
| Pharmedartis GmbH | 32 | 1 |
| Shire Plc | 33 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Drug Profiles | 34 | 23 |
| BaxB-01 Drug Profile | 34 | 1 |
| BaxG-03 Drug Profile | 35 | 1 |
| BaxM-159 Drug Profile | 36 | 1 |
| emricasan Drug Profile | 37 | 6 |
| flavokawain A Drug Profile | 43 | 1 |
| Granzyme B/VEGF Drug Profile | 44 | 1 |
| HaA-4 Drug Profile | 45 | 1 |
| nivocasan Drug Profile | 46 | 1 |
| NVX-207 Drug Profile | 47 | 1 |
| NWL-53 Drug Profile | 48 | 1 |
| plinabulin Drug Profile | 49 | 4 |
| Recombinant Protein to Activate CASP3 and CASP9 for Oncology Drug Profile | 53 | 1 |
| Small Molecule to Activate Caspase-3 for Oncology Drug Profile | 54 | 1 |
| Small Molecules to Activate Caspase 3 for Oncology Drug Profile | 55 | 1 |
| Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease Drug Profile | 56 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Dormant Projects | 57 | 5 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Discontinued Products | 62 | 1 |
| Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Featured News &Press Releases | 63 | 13 |
| Jun 28, 2016: BeyondSprings Global Phase III Non-Small Cell Lung Cancer Clinical Trial for Plinabulin Launches in China | 63 | 1 |
| May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication | 63 | 1 |
| May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO | 64 | 1 |
| May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial | 65 | 2 |
| Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data | 67 | 1 |
| Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting | 68 | 1 |
| Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering &Investment Forum in NYC | 68 | 1 |
| Feb 08, 2016: BeyondSpring Pharmaceuticals Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC | 68 | 1 |
| Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis | 69 | 1 |
| Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis | 70 | 1 |
| Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase | 71 | 1 |
| Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial | 71 | 2 |
| Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR s 2016 Tumor Microenvironment Special Conference | 73 | 1 |
| Dec 21, 2015: BeyondSpring Pharmaceuticals Granted CTA by CFDA to initiate China Arm of Global Phase III Trial of Lead Asset Plinabulin | 74 | 1 |
| Nov 17, 2015: BeyondSpring Data Demonstrating Activity of Plinabulin in Kras-Mutant Tumors Presented at AACR-NCI-EORTC International Conference 2015 | 75 | 1 |
| Appendix | 76 | 2 |
| Methodology | 76 | 1 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Expert Panel Validation | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 77 | 1 |